Navigation Links
Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries

NEWTON, Mass., June 3 /PRNewswire-FirstCall/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and POWREX Corporation have entered into an exclusive distributorship agreement whereby POWREX will market, sell and service Microfluidizer(R) high shear fluid processors in the pharmaceutical, biotechnology and energy industries throughout Japan.

Japan is the second-largest individual country pharmaceutical market in the world, and is a clear leader in innovative energy technologies, including fuel cells and photovoltaics. With this agreement, POWREX customers throughout Japan will be able to take wider advantage of the unique benefits provided by Microfluidizer high shear fluid processors to improve quality and efficiency in the lab as well as production.

POWREX will distribute the entire line of Microfluidizer top-down processors, which represents the widest range of pharmaceutical processors available, as well as novel Microfluidics Reaction Technology (MRT) for bottom-up creation of nanoparticles and efficient nanoencapsulation via continuous crystallization and chemical reactions.

"Microfluidics is honored to partner with such a respected corporation as POWREX," said Michael C. Ferrara, Microfluidics Chief Executive Officer. "We believe Microfluidizer processors are the undisputed gold standard in the biopharma industry, and MRT represents a tremendous opportunity particularly for energy researchers. We believe POWREX is well positioned to bring these technologies to a market eager for solutions."

Established in 1950 as Fuji Kikai Kohgyo Co, Ltd., and based in Hyogo, POWREX has grown over the past half-century to become one of the largest processing technologies companies in Japan. POWREX partners with its customers to deliver value-added original powder processing solutions including hardware, software and engineering services. By supplementing these core offerings with Microfluidics technology, POWREX will provide a more complete suite of best-in-class processors and scientific expertise to support customers' demanding research requirements.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.

About Microfluidics

Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. Microfluidics is a leader in innovative technology and comprehensive solutions for formulations requiring repeatability and for the production of uniformly distributed nanoparticles.

Microfluidics has been a worldwide supplier of Microfluidizer(R) high shear fluid processing systems to the biotechnology, pharmaceutical, chemical and cosmetics industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at any of three Microfluidics facilities. Visit, email or contact Microfluidics at 800.370.5452 for application information.

SOURCE Microfluidics International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GEN Reports on Growing Reliance on Microfluidics Technology
2. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
3. Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila
4. SPO Medical Expands Professional Product Offering
5. Cadient Interactive Expands Creative Leadership with New Associate Director
6. Environmental Tectonics Corporation Expands BioMedical Systems Division Sales Staff
7. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
8. Resonant Medical Expands Sales Organization with Appointment of Vice President of Global Sales and Marketing
9. SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
10. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
11. Microtest Labs Expands Clean Room, Contamination Testing Services
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society ... one of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The ... where ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):